Start: February 15, 2022
End: May 2025
Research suggests that low levels of glutathione, a protective substance made in the body, may be linked to Alzheimer's disease. Glutathione levels can be increased by taking supplements of glycine and cysteine, which combine in the body to make glutathione. This clinical trial will evaluate the effects of glycine-cysteine supplements in people with Alzheimer's disease. Participants will be randomly assigned to receive supplements of either glycine-cysteine or a placebo for 24 weeks. Participants will undergo MRI and PET brain imaging scans, assessments, and tests so researchers can measure changes in cognition, glutathione levels, brain cell energy use, and brain inflammation.
Minimum Age: 55 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Baylor College of Medicine
Houston, TX 77030
RecruitingRajagopal V Sekhar, MD
Lead: Baylor College of Medicine
Source: ClinicalTrials.gov ID: NCT04740580